Treatment interventions for Parkinson's disease: An evidence based assessment

Lancet

Volumn 359, Issue 9317, 2002, Pages 1589-1598

  Rascol, Olivier ^a   Goetz, Christopher ^b   Koller, William ^c   Poewe, Werner ^d   Sampaio, Cristina ^e  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF INNSBRUCK   (Austria)

^e INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BENSERAZIDE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA; CISAPRIDE; DIHYDROERGOCRYPTINE; DOMPERIDONE; DONEPEZIL; DOPA DECARBOXYLASE INHIBITOR; DOPAMINE RECEPTOR STIMULATING AGENT; ETILEFRINE; FLAVOXATE; FLUDROCORTISONE; GALANTAMINE; LEVODOPA; LISURIDE; METOCLOPRAMIDE; MIDODRINE; OXYBUTYNIN; PERGOLIDE; PRAMIPEXOLE; PRAZOSIN; PROPIVERINE; RIVASTIGMINE; ROPINIROLE; TACRINE; TOLTERODINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

CLINICAL TRIAL; CONSTIPATION; DECISION MAKING; DEMENTIA; DEPRESSION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; HUMAN; MOTOR CONTROL; NAUSEA; NEUROSURGERY; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PARKINSONISM; PHYSIOTHERAPY; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; URINARY DYSFUNCTION;

EID: 0037018742     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)08520-3     Document Type: Review

References (103)

1. Management of Parkinson's disease: An evidence-based review
2. Primate models of movement disorders of basal ganglia origin
3. Dopamine agonists: Their role in the management of Parkinson's disease
4. The pharmacology of selegiline
5. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease
6. Anticholinergic drugs and amantadine in the treatment of Parkinson's disease
7. N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease
8. Surgery for Parkinson disease: A critical evaluation of the state of the art
9. Cell replacement strategies for neurodegenerative disorders
10. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with (18)fluorodopa-PET
11. Potential of neuroprotective therapy in Parkinson's disease
12. Drug treatment effects on disease progression
13. Effect of deprenyl on the progression of disability in early Parkinson's diseases
14. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
15. The effect of deprenyl and levodopa on the progression of Parkinson's disease
16. Levodopa in Parkinson's disease. Neurotoxicity issue laid to rest?
17. Unified Parkinson's disease rating scale
18. Modification of parkinsonism: Chronic treatment with levodopa
19. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: Three year interim report
20. Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study
21. Pramipexole versus levodopa as initial treatment for Parkinson's disease: A randomized controlled trial
22. Immediate-release and controlled-release carbidopa/levodopa in PD: A 5-year randomized multicenter study
23. Alpha-dihydroergocryptine in the treatment of de novo parkinsonian patients: Results of a multicentre, randomised, double-blind, placebo-controlled study
24. Pergolide monotherapy in the treatment of early Parkinson's disease: A randomized, controlled study
25. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease
26. Ropinirole for the treatment of early Parkinson's disease
27. Impact of deprenyl and tocopherol treatment of Parkinson's disease in DATATOP subjects not requiring levodopa
28. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease
29. Low dose bromocriptine therapy in Parkinson's disease: Double-blind, placebo-controlled study
30. Amantadine in Parkinson's disease: A double-blind, placebo-controlled, crossover study with long-term follow-up
31. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease
32. And the international Pramipexole-Bromocriptine study group. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease
33. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease
34. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease
35. Efficacy, safety and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: Double-blind, placebo-controlled, randomized, multicenter study
36. Tolcapone in stable Parkinson's disease: Efficacy and safety of long-term treatment
37. Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson's disease treated with levodopa-carbidopa
38. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations
39. Controlled release long-acting levodopa/carbidopa combination in Parkinson's disease patients with and without motor fluctuation
40. Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson's disease
41. Parkinson's disease: Cogentin with Sinemet, a better response
42. Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson's disease
43. A randomised double-blind placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-stat events
44. Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease
45. Unilateral pallidotomy in Parkinson's disease: A randomized, single-blind, multicenter trial
46. Transplantation of fetal dopamine neurons in Parkinson's disease: One-year clinical and neuropsychological observations in two patients with putaminal implants
47. Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease
48. Outcome following intrastriatal fetal mesencepahalic grafts for Parkinson's patients is directly related to the volume of grafted tissue
49. Transplantation of embryonic dopamine neurons for severe parkinson's disease
50. Outcome after stereotactic thalamotomy for parkinsonian, essential and other types of tremor
51. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor
52. Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's disease: Results of randomized, blinded pilot study
53. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease
54. Multicentre European study of thalamic stimulation in parkinsonian and essential tremor
55. Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole
56. Sleep attacks and Parkinson's disease treatment
57. Levodopa monotherapy can induce "sleep attacks" in Parkinson's disease patients
58. Sudden daytime sleep onset in Parkinson's disease: Polysomnographic recordings
59. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
60. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: 6-month interim report of a 3-year study
61. Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients
62. Pleuropulmonary fibrosis due to bromocriptine tratment for Parkinson's disease
63. Pergolide-induced retroperitoneal fibrosis
64. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia
65. Rating scales for dyskinesia in Parkinson's disease
66. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease
67. A multicenter trial of ropinirole adjunct treatment for Parkinson's disease
68. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease with the "wearing-off" phenomenon: A double-blind, placebo-controlled, multicenter trial
69. Entacapone prolongs levodopa response in a one-month double-blind study in parkinsonian patients with levodopa related fluctuations
70. Pen injected apomorphine against off phenomena in late Parkinson's disease: A double blind, placebo controlled study
71. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
72. Amantadine for levodopa-induced dyskinesias: A 1-year follow-up study
73. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: A double-blind, placebo-controlled study
74. Beneficial effects of amantadine on levodopa-induced dyskinesia in Parkinson's disease
75. Stereotactic pallidotomy for the treatment of Parkinson's disease: Efficacy and adverse effects at 6-months in 26 patients
76. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesia in Parkinson's disease
77. Continuous dopamine-receptor stimulation in early Parkinson's disease
78. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications
79. The Sydney multicentre study of Parkinson's disease: A randomized, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa
80. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: A five year follow-up
81. Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects: Long-term results of the PRADO study
82. Early combination of bromocriptine and levodopa in Parkinson's disease: A prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage
83. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease
84. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients
85. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease: A multicenter 5-year study
86. A population-based investigation of Parkinson's disease with and without dementia: Relationship to age and gender
87. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop
88. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study
89. Parkinson's disease: Drug-induced psychiatric states
90. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease
91. Clozapine in drug-induced psychosis in Parkinson's disease
92. Olanzapine and clozapine: Comparative effects on motor function in hallucinating PD patients
93. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry
94. Quetiapine: A review of its clinical potential in the management of psychotis symptoms in Parkinson's disease
95. Depression in Parkinson's disease: An update
96. Antidepressive treatment in Parkinson's disease: A controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-Dopa
97. Moclobemide and selegeline in the treatment of depression in Parkinson's disease
98. Prevalence of orthostatic hypotension in Parkinson's disease
99. Neurogenic orthostatic hypotension: A double-blind, placebo controlled study with midodrine
100. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension: A randomized, placebo-controlled multicenter study
101. A controlled study with Dihydergot on patients with orthostatic dysregulation